CollabRx and OncoDNA Partner in Molecular Diagnostics

San Francisco, Calif., April 4, 2013 – CollabRx, Inc. (NASDAQ: CLRX), is a company for data analytics and its main focus is on informing on making clinical decisions in molecular medicine, and OncoDNA, SA, a company from Belgium that is providing DNA NGS tests (next-generation sequencing) for clinical use in the field of cancer, announced their multi-year contract for purchasing CollabRx’s SaaS-based technology and other resources to be used in complementation with OncoDNA’s panels for cancer mutation.

These two companies are developing a medical solution and combined test, by comparing the results from OncoDNA’s panels for cancer mutation with the clinical knowledge from CollabRX.